Overview
Lung disease treatment firm's Q4 total worldwide revenue fell 5% yr/yr but beat analyst expectations
Adjusted EBITDA loss for Q4 narrowed compared to last year
Company refinanced debt with a new $60 mln credit facility extending to 2031
Outlook
Pulmonx expects 2026 revenue between $90 mln and $92 mln
Company anticipates 2026 gross margin to be approximately 75%
Pulmonx projects 2026 operating expenses between $113 mln and $115 mln
Result Drivers
INTERNATIONAL GROWTH - International revenue increased by 8% in Q4 2025, offsetting some of the decline in U.S. revenue
COST RESTRUCTURING - Pulmonx reduced operating expenses by 11% in Q4 2025 through a cost restructuring initiative
Company press release: ID:nGNXdwms1
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Total Worldwide Revenue | Beat | $22.60 mln | $21.73 mln (6 Analysts) |
Q4 EPS | -$0.25 | ||
Q4 Net Income | -$10.43 mln | ||
Q4 Gross Profit | $17.54 mln | ||
Q4 Income From Operations | -$9.90 mln | ||
Q4 Pretax Profit | -$10.24 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Pulmonx Corp is $4.50, about 194.1% above its March 3 closing price of $1.53
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments